253 related articles for article (PubMed ID: 16199439)
21. N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell invasion through suppressing NF-KB activation and inhibiting matrix metalloproteinase-9 expression.
Kang H; Lee M; Choi KC; Shin DM; Ko J; Jang SW
J Cell Biochem; 2012 Sep; 113(9):2845-55. PubMed ID: 22488409
[TBL] [Abstract][Full Text] [Related]
22. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
Ottewell PD; Deux B; Mönkkönen H; Cross S; Coleman RE; Clezardin P; Holen I
Clin Cancer Res; 2008 Jul; 14(14):4658-66. PubMed ID: 18628481
[TBL] [Abstract][Full Text] [Related]
23. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer.
Hiraga T; Myoui A; Choi ME; Yoshikawa H; Yoneda T
Cancer Res; 2006 Feb; 66(4):2067-73. PubMed ID: 16489006
[TBL] [Abstract][Full Text] [Related]
24. Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis.
Koblinski JE; Kaplan-Singer BR; VanOsdol SJ; Wu M; Engbring JA; Wang S; Goldsmith CM; Piper JT; Vostal JG; Harms JF; Welch DR; Kleinman HK
Cancer Res; 2005 Aug; 65(16):7370-7. PubMed ID: 16103089
[TBL] [Abstract][Full Text] [Related]
25. Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites.
Sabichi AL; Xu H; Fischer S; Zou C; Yang X; Steele VE; Kelloff GJ; Lotan R; Clifford JL
Clin Cancer Res; 2003 Oct; 9(12):4606-13. PubMed ID: 14555536
[TBL] [Abstract][Full Text] [Related]
26. N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma.
Sheikh MS; Shao ZM; Li XS; Ordonez JV; Conley BA; Wu S; Dawson MI; Han QX; Chao WR; Quick T
Carcinogenesis; 1995 Oct; 16(10):2477-86. PubMed ID: 7586155
[TBL] [Abstract][Full Text] [Related]
27. Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.
Thai le M; Labrinidis A; Hay S; Liapis V; Bouralexis S; Welldon K; Coventry BJ; Findlay DM; Evdokiou A
Cancer Res; 2006 May; 66(10):5363-70. PubMed ID: 16707463
[TBL] [Abstract][Full Text] [Related]
28. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
McGuire KP; Ngoubilly N; Neavyn M; Lanza-Jacoby S
J Surg Res; 2006 May; 132(2):208-13. PubMed ID: 16580691
[TBL] [Abstract][Full Text] [Related]
29. Cholecalciferol (vitamin D3) and the retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) are synergistic for chemoprevention of prostate cancer.
Tokar EJ; Ancrile BB; Ablin RJ; Webber MM
J Exp Ther Oncol; 2006; 5(4):323-33. PubMed ID: 17024972
[TBL] [Abstract][Full Text] [Related]
30. Quality control for HPLC assay and surrogate end point biomarkers from the fenretinide (4-HPR) breast cancer prevention trial.
Formelli F
J Cell Biochem Suppl; 2000; 34():73-9. PubMed ID: 10762018
[TBL] [Abstract][Full Text] [Related]
31. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients.
Torrisi R; Pensa F; Orengo MA; Catsafados E; Ponzani P; Boccardo F; Costa A; Decensi A
Cancer Res; 1993 Oct; 53(20):4769-71. PubMed ID: 8402658
[TBL] [Abstract][Full Text] [Related]
32. Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line.
Appierto V; Cavadini E; Pergolizzi R; Cleris L; Lotan R; Canevari S; Formelli F
Br J Cancer; 2001 Jun; 84(11):1528-34. PubMed ID: 11384104
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of tumor formation by snake venom disintegrin.
Yang RS; Tang CH; Chuang WJ; Huang TH; Peng HC; Huang TF; Fu WM
Toxicon; 2005 Apr; 45(5):661-9. PubMed ID: 15777962
[TBL] [Abstract][Full Text] [Related]
34. Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients.
Formelli F; Carsana R; Costa A; Buranelli F; Campa T; Dossena G; Magni A; Pizzichetta M
Cancer Res; 1989 Nov; 49(21):6149-52. PubMed ID: 2529028
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer cells induce osteoblast apoptosis: a possible contributor to bone degradation.
Mastro AM; Gay CV; Welch DR; Donahue HJ; Jewell J; Mercer R; DiGirolamo D; Chislock EM; Guttridge K
J Cell Biochem; 2004 Feb; 91(2):265-76. PubMed ID: 14743387
[TBL] [Abstract][Full Text] [Related]
36. N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase.
Wang H; Maurer BJ; Reynolds CP; Cabot MC
Cancer Res; 2001 Jul; 61(13):5102-5. PubMed ID: 11431347
[TBL] [Abstract][Full Text] [Related]
37. N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL).
Faderl S; Lotan R; Kantarjian HM; Harris D; Van Q; Estrov Z
Leuk Res; 2003 Mar; 27(3):259-66. PubMed ID: 12537979
[TBL] [Abstract][Full Text] [Related]
38. Reactive oxygen species mediate N-(4-hydroxyphenyl)retinamide-induced cell death in malignant T cells and are inhibited by the HTLV-I oncoprotein Tax.
Darwiche N; Abou-Lteif G; Bazarbachi A
Leukemia; 2007 Feb; 21(2):261-9. PubMed ID: 17122865
[TBL] [Abstract][Full Text] [Related]
39. Carcinoma cell lines resistant for growth inhibition and apoptosis to retinoic acid are responsive to 4-hydroxy-phenyl-retinamide: correlation with tissue transglutaminase.
Chiantore MV; Giandomenico V; De Luca LM
Biochem Biophys Res Commun; 1999 Jan; 254(3):636-41. PubMed ID: 9920792
[TBL] [Abstract][Full Text] [Related]
40. Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome.
Formelli F; Camerini T; Cavadini E; Appierto V; Villani MG; Costa A; De Palo G; Di Mauro MG; Veronesi U
Cancer Epidemiol Biomarkers Prev; 2003 Jan; 12(1):34-41. PubMed ID: 12540501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
